The European Union has taken advantage of the goodwill and generosity of the United States, and American Taxpayers, since its inception.

Despite President Trump's historically unprecedented victory by signing a landmark trade deal in July of this year, the European Union continues to take advantage of the United States, primarily regarding pharmaceutical patents and intellectual property rights.

Europe's Regulatory Data Protection (RDP) cuts will have a devastating effect on innovation, and American taxpayers will get stuck footing the bill for almost all future pharmaceutical innovations.

If the EU is not stopped, America’s pharma bill is about to get a lot more expensive. $64 billion more expensive.

The European Union and American leadership meet tomorrow December 10th.